1 Day
Source:
The Boston Globe
Source: The Boston Globe
1 DayThe Boston Globe
Source: The Boston Globe
1 DayReady to play
Ready to play
Moderna announced positive results from a late-stage trial of a personalized mRNA vaccine combined with Merck’s Keytruda for melanoma treatment, showing potential to extend survival and prevent cancer recurrence. The trial involved over 1,000 patients and marked a significant advancement in personalized cancer immunotherapy. If approved, this therapy could transform Moderna’s focus from infectious diseases to oncology, with broader applications in other cancers under investigation.
Notice: This Is an AI-Generated Summary
Comments (0)